Dr. Sheth graduated from Johns Hopkins University and the University of Pennsylvania School of Medicine. He was an intern at Brigham and Women's Hospital and a neurology resident and chief resident at Partners Neurology (Massachusetts General and Brigham & Women's Hospitals). After a fellowship in vascular neurology and neuro-critical care at Harvard, he was appointed the first neurology trained neuro-intensivist at the University of Maryland and R Adams Cowley Shock Trauma Center. He moved to Yale as the founding chief of the Division of Neurocritical Care and Emergency Neurology and Chief of Clinical Research for the Department of Neurology.
His interests are in the advancement of therapies and care of patients with devastating acute neurological syndromes, especially those complicated by brain swelling and hemorrhage. He is a nationally recognized clinical and translational scientist and has directed a number of multicenters studies testing novel therapies against brain swelling, stroke, and hemorrhage. His research group also develops novel imaging and serum based biomarkers for the neuro-ICU and furthers understanding of prognosis. His research has been funded by the NIH, American Academy of Neurology, American Heart Association, US Army, and the Passano Foundation. He is the co-chair of several national working groups developing guidelines in malignant infarction.
Accepts new patients? Yes
Patient Type: Adult
Referrals: MD to MD Consult
Patient Care Organizations
Neurology AB of Psychiatry & Neurology (2008)
Vascular Neurology AB of Psychiatry & Neurology (2009)
Neurocritical Care United Council for Neurologic Subspecialties (2010)
|Diseases of the Nervous System||A Study With SAGE-547 for Super-Refractory Status Epilepticus|
|Diseases of the Nervous System, Diseases of the Respiratory Systems||SETPOINT 2 Stroke-Related Early Tracheostomy versus Prolonged Orotracheal Intubation in Neurocritical Care Trial 2|
|Diseases of the Cardiovascular System||Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial|
|Diseases of the Nervous System||Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial|